Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRSN |
---|---|---|
09:32 ET | 377 | 0.9395 |
09:35 ET | 13080 | 0.94 |
09:42 ET | 1200 | 0.9495 |
09:46 ET | 3261 | 0.94 |
09:50 ET | 12000 | 0.96 |
09:51 ET | 200 | 0.9401 |
09:55 ET | 1900 | 0.94 |
09:57 ET | 6695 | 0.96 |
10:00 ET | 37109 | 0.9562 |
10:02 ET | 18646 | 0.9562 |
10:06 ET | 100 | 0.969 |
10:09 ET | 34583 | 0.9567 |
10:22 ET | 190 | 0.96 |
10:27 ET | 100 | 0.9701 |
10:29 ET | 37147 | 1.03 |
10:33 ET | 5714 | 1.02 |
10:36 ET | 600 | 1 |
10:40 ET | 4990 | 0.9601 |
10:44 ET | 650 | 1.0457 |
10:45 ET | 200 | 1.0369 |
10:47 ET | 2655 | 1.023 |
10:49 ET | 5600 | 0.978999 |
10:51 ET | 550 | 0.979 |
10:56 ET | 100 | 0.978999 |
11:00 ET | 250 | 0.98 |
11:03 ET | 200 | 0.9751 |
11:14 ET | 1000 | 0.96 |
11:23 ET | 100 | 0.9601 |
11:30 ET | 10673 | 0.95 |
11:32 ET | 900 | 0.9301 |
11:45 ET | 100 | 0.9401 |
11:52 ET | 1000 | 0.954199 |
11:54 ET | 100 | 0.9401 |
11:56 ET | 300 | 0.9301 |
12:01 ET | 1000 | 0.93 |
12:03 ET | 2310 | 0.933052 |
12:08 ET | 2554 | 0.9076 |
12:10 ET | 2000 | 0.933406 |
12:19 ET | 10024 | 0.94 |
12:24 ET | 33096 | 0.95 |
12:26 ET | 400 | 0.9579 |
12:28 ET | 38280 | 0.96 |
12:33 ET | 100 | 0.95505 |
12:42 ET | 100 | 0.9605 |
12:44 ET | 1500 | 0.96 |
12:48 ET | 26190 | 0.99 |
12:53 ET | 100 | 0.9801 |
12:57 ET | 100 | 0.9801 |
01:00 ET | 200 | 0.9801 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neurosense Therapeutics Ltd | 19.3M | -2.2x | --- |
Acurx Pharmaceuticals Inc | 19.3M | -1.2x | --- |
Goldenwell Biotech Inc | 19.8M | -153.8x | --- |
NanoViricides Inc | 19.8M | -1.8x | --- |
CytoMed Therapeutics Ltd | 26.7M | -11.9x | --- |
Finch Therapeutics Group Inc | 19.0M | -1.4x | --- |
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.44 |
Book Value | $-0.11 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.